Connect your AI

Scholar Rock SRRK Retained Earnings

Retained Earnings at other companies

BiogenBIIB

$20.87B+7.0%

Edgewise Therapeutics, Inc.EWTX

-$595.38M-42.0%

PTC TherapeuticsPTCT

-$2.97B-6.7%

Dyne Therapeutics, Inc.DYN

-$1.52B-42.4%

Catalyst PharmaceuticalCPRX

$523.35M+53.1%

Cogent Biosciences, Inc.COGT

-$1.29B-38.0%

Other financials

Income statement

Revenue-—

Operating income-$102.0M-32.3%

Net income-$105.5M-41.2%

EPS (diluted)-$0.83-23.9%

Balance sheet

Cash & equivalents$430.5M+212%

Total debt$205.7M+226%

Total equity$276.0M-11.6%

Total assets$535.3M+31.3%

Cash flow

Operating cash flow-$82.1M-4.4%

CapEx$68.0K-74.9%

Free cash flow-$82.2M-4.1%

Valuation

Market cap$5.67B+85.5%

Profitability

Operating margin-231.8%—

Net margin-236.9%—

FCF margin-309.1%—

Returns & leverage

Return on equity-138.9%+60.1pp

Debt / equity0.7×+0.5×

Current ratio8.6×-1.6×

Where this comes from

Reported directly by Scholar Rock in its filing.

Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.

The official record: Scholar Rock’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scholar Rock's retained earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Scholar Rock's retained earnings?: Scholar Rock (SRRK) reported retained earnings of -$1.41B in Q1 2026.
How has Scholar Rock's retained earnings changed year-over-year?: Scholar Rock's retained earnings decreased by 41.0% year-over-year, from -$997.44M to -$1.41B.
What is the long-term trend for Scholar Rock's retained earnings?: Over 5 years (2020 to 2025), Scholar Rock's retained earnings has grown at a 39.7% compound annual growth rate (CAGR), from -$244.33M to -$1.3B.
What does retained earnings mean?: Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.